



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/621,988	07/17/2003	Yaron Keidar	50161/AW/W112	2062
23363	7590	09/05/2007	EXAMINER	
CHRISTIE, PARKER & HALE, LLP PO BOX 7068 PASADENA, CA 91109-7068				PEFFLEY, MICHAEL F
ART UNIT		PAPER NUMBER		
3739				
MAIL DATE		DELIVERY MODE		
09/05/2007		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/621,988	KEIDAR, YARON
	<b>Examiner</b>	<b>Art Unit</b>
	Michael Peffley	3739

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 26 June 2007.
- 2a) This action is FINAL.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-45 is/are pending in the application.
- 4a) Of the above claim(s) 17-45 is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1-16 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 17 July 2003 is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All
  - b) Some \*
  - c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

Applicant's amendments and comments, received June 26, 2007, have been fully considered by the examiner. The following is a complete response to the June 26, 2007 communication.

***Election/Restrictions***

Claims 17-45 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on September 1, 2005.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-10 and 12-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Marcus et al (5,295,484) in view of the teachings of Panescu et al (2003/0078509) and Maguire et al (6,514,249).

Marcus et al discloses a catheter for mapping and ablating cardiac tissue, the catheter having an ultrasound transducer mounted at the distal end. The transducer may take a variety of shapes, and includes a back surface mounted to the catheter for directing energy in a forward direction. In Figures 8 and 9, the transducer is mounted to the distal end and has a flat face for directing energy forward (see col. 7, lines 50-55). Figure 6 shows a rectangular-faced transducer with the back surface mounted in the

Art Unit: 3739

catheter body. Marcus et al also disclose electrodes on the distal catheter surface for sensing a location (e.g. through mapping) in the heart. However, Marcus et al do not specifically disclose that the electrodes function as sensors to sense a location and an orientation of the transducer within the patient, and Marcus et al also fail to specifically disclose a layered transducer with a central layer adapted to contract and expand to control the direction of ultrasonic energy. With regard to the various sizes for the transducer and the spacing for the sensors, the examiner maintains that such parameters would be a matter of obvious design choice dependent on the particular procedure. It is noted that applicant's specification has not indicated any particular criticality or unexpected result associated with these values.

Panescu et al, as addressed in previous Office actions, also disclose a catheter for the mapping and ablation of cardiac tissue. In particular, Panescu et al teach that it is advantageous to provide such a catheter system with a sensor means to precisely locate the catheter device, as well as determine the orientation of the catheter (and inherently its components) within the body. See paragraphs [0103-0104].

Regarding the specific ultrasound transducer, Maguire et al disclose another cardiac ablation catheter, similar to Marcus et al, that uses ultrasound energy for treating tissue. In particular, Maguire et al teach that it is advantageous to provide the ultrasonic transducer with inner and outer layers and a central layer that expands and contracts to control the application of energy to tissue (see col. 33, lines 40-50).

To have provided the Marcus et al catheter with a location sensor means to precisely determine the location and orientation of the catheter within the body to assure

treatment of a desired tissue target would have been an obvious modification for one of ordinary skill in the art in view of the teaching of Panescu et al. To have further provided the Marcus et al catheter with a layered transducer having a vibrating central layer for controlling the application of energy to tissue would have been an obvious design consideration for one of ordinary skill in the art in view of the teaching of Maguire et al.

Claim 11 is rejected under 35 U.S.C. 103(a) as being unpatentable over Marcus et al ('484), Panescu et al ('509) and Maguire et al ('249) as applied to claim 1 above, and further in view of the teaching of Chandrasekaran et al (6,394,956).

The combination of the Marcus et al catheter with the Panescu et al and Maguire et al teachings has been addressed previously. Marcus et al disclose electrodes on the end of the catheter, but fail to specifically disclose the ultrasound transducer mounted on the surface of the electrode. Rather, the electrodes are provided in proximity to the transducer.

Chandrasekaran et al disclose another mapping and ablation catheter and specifically teach that it is known to mount an ultrasound transducer (34) directly to an electrode (38) at the distal end of the catheter assembly. Such a mounting allows the use of the transducer in direct relationship with the electrode.

To have provided the Marcus et al device with a tip electrode and the transducer mounted to the transducer, as fairly taught by Chandrasekaran et al, to allow for the use

Art Unit: 3739

of RF and ultrasound energy at the same location would have been an obvious consideration for one of ordinary skill in the art.

Claim 16 is rejected under 35 U.S.C. 103(a) as being unpatentable over Marcus et al ('484) and Panescu et al ('509) and Maguire et al ('249) as applied to claim 1 above, and further in view of the teaching of Crowley et al (6,004,269).

Again, the combination of the Marcus et al catheter with the Panescu et al and Maguire et al teachings has been addressed. Neither catheter specifically provides for a fluid channel to provide an irrigant to tissue.

Crowley et al disclose another ablation catheter that includes an ultrasound transducer and electrodes. In particular, Crowley et al teach of the advantages of providing a flushing or ablation enhancement solution through a lumen in the catheter (col. 10, lines 38-45).

To have provided the Marcus et al catheter, as modified by the teaching of Panescu et al, with a fluid lumen to provide an irrigant and/or ablation enhancement fluid to enhance the ablation of tissue would have been an obvious consideration for one of ordinary skill in the art in view of the teaching of Crowley et al.

#### ***Response to Arguments***

Applicant's arguments with respect to claims 1-16 have been considered but are moot in view of the new ground(s) of rejection.

***Conclusion***

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Peffley whose telephone number is (571) 272-4770. The examiner can normally be reached on Mon-Fri from 7am-4pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Linda Dvorak can be reached on (571) 272-4764. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3739

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael Peffley/  
Primary Examiner  
Art Unit 3739

/mp/  
August 21, 2007